BALTIMORE, Aug. 20, 2019 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced today that its Board of Directors has declared a quarterly dividend of $0.76 per share payable September 27, 2019 to stockholders of record as of the close of business on September 13, 2019.
ABOUT T. ROWE PRICE Founded in 1937, Baltimore-based T. Rowe Price Group, Inc. (troweprice.com), is a global investment management organization with $1.14 trillion in assets under management as of July 31, 2019. The organization provides a broad array of mutual funds, subadvisory services, and separate account management for individual and institutional investors, retirement plans, and financial intermediaries. The company also offers sophisticated investment planning and guidance tools. T. Rowe Price's disciplined, risk-aware investment approach focuses on diversification, style consistency, and fundamental research.
Pomerantz LLP is investigating claims on behalf of investors of Li Auto Inc. ("Li Auto" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Ralph & Pat Plumb, owners of the Brick Alley Pub, announced today that they've entered into an agreement to sell the Brick Alley Pub to The Heritage Restaurant Group, formerly 1899 Ventures, a Newport Rhode Island based restaurant group.
The Brick...
Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Pomerantz LLP is investigating claims on behalf of investors of Perion Network Ltd. ("Perion" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Pomerantz LLP is investigating claims on behalf of investors of TMC the metals company Inc. ("TMC" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. ...
Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
